BlueCrest Capital Management’s Pacira BioSciences PCRX Stock Holding History

BlueCrest Capital Management’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-14,131	Closed	-$695K	–	1284
2018 Q3	$695K	Sell	14,131 -2,446	-15%	-$106K	0.02%	592
2018 Q2	$531K	Buy	16,577 +2,421	+17%	+$83.6K	0.01%	804
2018 Q1	$441K	Buy	14,156 +621	+5%	+$22.1K	0.01%	842
2017 Q4	$618K	Buy	13,535 +1,007	+8%	+$39.9K	0.02%	480
2017 Q3	$470K	Buy	12,528 +2,158	+21%	+$86.8K	0.02%	533
2017 Q2	$495K	Buy	+10,370	New	+$481K	0.02%	589

Other funds holding PCRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BlueCrest Capital Management's PCRX Position: Q4 2018 in Review

BlueCrest Capital Management sold out of Pacira BioSciences (PCRX) in Q4 2018, closing a stake of 14,131 shares — an estimated $695K sold.

BlueCrest Capital Management first reported a position in PCRX in Q2 2017 and held it in 6 quarters. The position peaked at $695K in Q3 2018. 208 funds tracked by Wall St. Rank hold PCRX as of Q4 2018.

BlueCrest Capital Management reported no remaining Pacira BioSciences position as of Q4 2018 after selling out during the quarter.
BlueCrest Capital Management sold 14,131 Pacira BioSciences shares in Q4 2018, an estimated $695K.
BlueCrest Capital Management first reported a position in Pacira BioSciences in Q2 2017 and held it in 6 quarters.
BlueCrest Capital Management's Pacira BioSciences position peaked at $695K in Q3 2018.
208 funds tracked by Wall St. Rank held Pacira BioSciences as of Q4 2018.

Based on BlueCrest Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.